Diabetes
Conference Recap
Glycemic Control in Type 2 Diabetes From ADA 2022
Dr Ildiko Lingvay reports on the ADA's changing standards of care for patients with diabetes and key studies in glycemic control, including...
Conference Recap
Key Studies on Diabetes Comorbidities From ADA 2022
Common comorbidities play a major role in diabetes management. Key studies at ADA 2022 examined how therapy and weight control influence kidney...
Conference Coverage
Type 1 diabetes control worse in racially segregated teens
Age and insulin delivery method, but not family income, also affected glycemic control for Black teens in poor neighborhoods.
Feature
New data, film highlight islet cell transplantation progress
A new documentary shows the human side of islet cell transplantation research for type 1 diabetes and follows encouraging data presentations at...
Expert Interview
Type 2 Diabetes and COVID-19
Commentary
iLet system simplifies insulin delivery for type 1 diabetes
Dr Anne Peters offers perspective on how the iLet automated insulin system works and can improve management for patients with type 1 diabetes.
Conference Coverage
Could a type 2 diabetes drug tackle kidney stones?
“If this association is proven, empagliflozin may be used to decrease the risk of kidney stones at least in those with type 2 diabetes, but maybe...
Latest News
What’s the best time of day to exercise? It depends on your goals
When you exercise can ultimately have a big effect in terms of strength, fat loss, heart health, mood, and quality of sleep.
From the Journals
Heart failure: Medicare cost sharing may put quadruple therapy out of reach
Patients’ out-of-pocket costs are highest for the most effective medications.
Conference Coverage
Ultra-processed: Doctors debate whether putting this label on foods is useful
Some experts say increased awareness and labeling of ultra-processed foods can only be a good thing. Others say that the classification system...
Conference Coverage
Experts elevate new drugs for diabetic kidney disease
A consensus statement from the ADA and KDIGO recommends more aggressive combined use of several newer, and costly, drug classes to slow...